The estimated Net Worth of Travis C Mickle is at least $1.42 Million dollars as of 25 May 2022. Travis Mickle owns over 13,000 units of Zevra Therapeutics Inc stock worth over $64,108 and over the last 10 years he sold KMPH stock worth over $0. In addition, he makes $1,360,170 as Chairman of the Board, President und Chief Executive Officer at Zevra Therapeutics Inc.
Travis has made over 12 trades of the Zevra Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 13,000 units of KMPH stock worth $56,940 on 25 May 2022.
The largest trade he's ever made was buying 110,000 units of Zevra Therapeutics Inc stock on 2 June 2020 worth over $20,900. On average, Travis trades about 9,550 units every 94 days since 2015. As of 25 May 2022 he still owns at least 11,034 units of Zevra Therapeutics Inc stock.
You can see the complete history of Travis Mickle stock trades at the bottom of the page.
Dr. Travis C. Mickle Ph.D. serves as Chairman of the Board, President, Chief Executive Officer of the Company. Dr. Mickle is a co-founder of our company and has served as a member of our Board since our inception in 2006 and chairman of our Board since November 2014. Dr. Mickle served as our president and chief scientific officer from 2006 to October 2010, and has served as our president and chief executive officer since October 2010. Prior to founding our company, Dr. Mickle spent five years with New River Pharmaceuticals, a specialty pharmaceutical company, where he was a senior research scientist from 2001 to 2002, the director of chemistry from 2002 to 2003 and the director of drug discovery and CMC from 2003 to 2005. Dr. Mickle received his Ph.D. degree from the University of Iowa and his B.A. degree from Simpson College. Our Board believes that Dr. Mickle’s leadership of our company since its inception, knowledge of our company as founder and experience with pharmaceutical companies provides him with the qualifications and skills to serve as a director of our company.
As the Chairman of the Board, President und Chief Executive Officer of Zevra Therapeutics Inc, the total compensation of Travis Mickle at Zevra Therapeutics Inc is $1,360,170. There are no executives at Zevra Therapeutics Inc getting paid more.
Travis Mickle is 46, he's been the Chairman of the Board, President und Chief Executive Officer of Zevra Therapeutics Inc since 2014. There are 10 older and 4 younger executives at Zevra Therapeutics Inc. The oldest executive at Zevra Therapeutics Inc is Richard W. Pascoe, 57, who is the Exec. Chairman.
Travis's mailing address filed with the SEC is C/O KEMPHARM, INC., 1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION, FL, 34747.
Over the last 10 years, insiders at Zevra Therapeutics Inc have traded over $0 worth of Zevra Therapeutics Inc stock and bought 3,083,371 units worth $9,282,809 . The most active insiders traders include Street Capital Master Fund,..., David S Tierney und Travis C Mickle. On average, Zevra Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $246,727. The most recent stock trade was executed by R. La Duane Clifton on 13 January 2023, trading 635 units of KMPH stock currently worth $3,689.
KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT™ technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm's prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm's co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.
Zevra Therapeutics Inc executives and other stock owners filed with the SEC include: